Ponte Vedra-based Cadrenal Therapeutics receives second FDA orphan drug designation

Cadrenal received a Orphan Drug Designation for its reversible anticoagulant tecarfarin

Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 9, 2024 Category: Pharmaceuticals Authors: James Cannon Source Type: news